A Trojan horse for thirsty tumours
Elie Dolgin • July 11, 2024
Joining a drug candidate to a protein that malignant cells naturally take up allowed one firm to come up with a potent anti-cancer therapy.
Read at Nature Outlook.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.